DuPont Merck Coumadin (warfarin) gains post-MI prevention of death and reinfarction indication.
Executive Summary
DUPONT MERCK COUMADIN POST-MI MORTALITY/HEART ATTACK PREVENTION INDICATION clears FDA on April 28 and will be launched by the company in June. Coumadin (warfarin) tablet and injectable formulations are indicated "to reduce the risk of death, recurrent myocardial infarction and thromboembolic events such as stroke or systemic embolization after myocardial infarction," labeling states.